ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Current state of Clostridium difficile treatment options.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 69 citations in OpenAlex.
- Encapsulation protocol for fecal microbiota transplantation.Frontiers in cellular and infection microbiology · 2024Article
- Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.Nature communications · 2021Article
- An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety.Molecules (Basel, Switzerland) · 2020Review
- Impact of Delayed Oral Vancomycin for SevereHospital pharmacy · 2019Article
- Carbohydrate Scaffolds for the Study of the Autism-associated Bacterium, Clostridium bolteae.Current medicinal chemistry · 2019Review
- Novel FR-900493 Analogues That Inhibit the Outgrowth ofACS omega · 2018Article
- Characterization of Bacteriophages Infecting Clinical Isolates ofFrontiers in microbiology · 2018Article
- Bezlotoxumab (Zinplava) forP & T : a peer-reviewed journal for formulary management · 2017Article
- Development of a subunit vaccine for prevention ofBiochemistry and biophysics reports · 2017Article
- Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, NonoperativeOpen forum infectious diseases · 2017Article
- Breakthroughs in the treatment and prevention of Clostridium difficile infection.Nature reviews. Gastroenterology & hepatology · 2016Review
- Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites.European journal of medicinal chemistry · 2015Article
- Clostridium difficile drug pipeline: challenges in discovery and development of new agents.Journal of medicinal chemistry · 2015Review
- Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile.Antimicrobial agents and chemotherapy · 2014Article
- The CD27L and CTP1L endolysins targeting Clostridia contain a built-in trigger and release factor.PLoS pathogens · 2014Article
- Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.Alimentary pharmacology & therapeutics · 2014Article
- Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.Therapeutic advances in chronic disease · 2014Review
- Could nitazoxanide be added to other essential medicines for integrated neglected tropical disease control and elimination?PLoS neglected tropical diseases · 2014Article
- Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Current topics in medicinal chemistry · 2014Review
- The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes.Genome biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent reports of reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for recurrent CDI that is common with all currently available treatment agents have posed a significant challenge to clinicians. Current recommendations include metronidazole for treatment of mild to moderate CDI and vancomycin for severe CDI. Results from small clinical trials suggest that nitazoxanide and teicoplanin may be alternative options to standard therapies, whereas rifaximin has demonstrated success in uncontrolled trials for the management of multiple recurrences. Anecdotal reports have also suggested that tigecycline might be useful as an adjunctive agent for the treatment of severe complicated CDI. Reports of resistance will likely limit the clinical use of fusidic acid and bacitracin and, possibly, rifaximin if resistance to this agent becomes widespread. Treatment of patients with multiple CDI recurrences and those with severe complicated CDI is based on limited clinical evidence, and new treatments or strategies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.